Revance Therapeutics, Inc. (30)

Browse by Contract Category

Contracts

Office Lease Agreement dated November 19, 2020 (Filed With SEC on November 20, 2020)
First Amendment to Exclusive Distribution Agreement (Filed With SEC on November 9, 2020)
Revance Therapeutics, Inc. Amended and Restated 2014 Inducement Plan (Filed With SEC on November 9, 2020)
Executive Employment Agreement effective July 23, 2020 by and between Revance Therapeutics, Inc. and Aubrey Rankin (Filed With SEC on November 9, 2020)
Loan Agreement, dated May 18, 2020, by and between Revance Therapeutics, Inc. and Hint, Inc (Filed With SEC on June 10, 2020)
License Agreement, dated December 4, 2018, by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd (Filed With SEC on February 28, 2019)
Fifth Amendment to Lease, dated July 1, 2020, by and between Revance Therapeutics, Inc. and BMR-Pacific Research Center LP (Filed With SEC on August 6, 2020)
Form of Lock-Up Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)
Form of Voting Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)
Revance Therapeutics, Inc. 2020 Management Bonus Plan (Filed With SEC on February 26, 2020)
Exclusive Distribution Agreement, dated January 10, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on February 26, 2020)
Executive Employment Agreement dated February 17, 2020 by and between Revance Therapeutics, Inc. and Dwight Moxie (Filed With SEC on February 26, 2020)
Separation Agreement effective January 8, 2020 by and between Revance Therapeutics, Inc. and Caryn G. McDowell (Filed With SEC on February 26, 2020)
Executive Employment Agreement effective December 1, 2019 and between Revance Therapeutics, Inc. and Dustin Sjuts (Filed With SEC on February 26, 2020)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 26, 2020)
Description of Registrants Securities (Filed With SEC on February 26, 2020)
Indenture, dated as of February 14, 2020, by and between Revance Therapeutics, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on February 14, 2020)
Underwriting Agreement, dated December 4, 2019, by and among the Company and the Underwriters (Filed With SEC on December 4, 2019)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 4, 2019)
Executive Employment Agreement effective October 13, 2019 by and between Revance Therapeutics, Inc. and Mark J. Foley (Filed With SEC on November 4, 2019)
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated effective October 13, 2019 (Filed With SEC on November 4, 2019)
Separation Agreement effective October 11, 2019 by and between Revance Therapeutics, Inc. and L. Daniel Browne (Filed With SEC on November 4, 2019)
Amendment #1 to the Collaboration and License Agreement dated August 22, 2019 between Revance Therapeutics, Inc. and Mylan Ireland Ltd (Filed With SEC on November 4, 2019)
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated Effective February 12, 2019 (Filed With SEC on May 9, 2019)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2019)
Revance Therapeutics, Inc. 2019 Management Bonus Plan (Filed With SEC on February 28, 2019)
Employment Agreement dated November 7, 2018 by and between Revance Therapeutics, Inc. and Cyril Allouche (Filed With SEC on February 28, 2019)
Executive Employment Agreement dated November 5, 2018 by and between Revance Therapeutics, Inc. and Tobin Schilke (Filed With SEC on February 28, 2019)
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2019)
Underwriting Agreement, dated January 16, 2019, by and among the Company and the Underwriters (Filed With SEC on January 17, 2019)